US FDA approves generic cholesterol-lowering pill
Nod for generic Crestor deals blow to AstraZeneca as price could drop 80-90%
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
THE US Food and Drug Administration (FDA) said on Wednesday that it had approved generic versions of the blockbuster cholesterol-lowering pill Crestor, rejecting a last-ditch and controversial effort by AstraZeneca to stop cheaper competition from reaching pharmacy shelves.
The move should considerably decrease the price of the drug and result in a sharp loss of market share for AstraZeneca. The brand-name drug has a retail price around US$260 a month, according to GoodRx.com. With multiple generics now coming onto the market, the price could eventually drop as much as 80 to 90 per cent.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
